NL
GILD icon

NorthAvenue LLC’s Gilead Sciences GILD Stock Holding History

NorthAvenue LLC’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759 Hold
6
– – ﹤0.01% 241
2026
Q1 		$837 Hold
6
– – ﹤0.01% 202
2025
Q4 		$737 Buy
+6
New +$729 ﹤0.01% 224

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

NorthAvenue LLC's GILD Position: Q2 2026 in Review

NorthAvenue LLC held its Gilead Sciences (GILD) position steady in Q2 2026 at 6 shares worth $759. The position accounts for ﹤0.01% of the portfolio, ranked #241.

NorthAvenue LLC first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $837 in Q1 2026. 508 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • NorthAvenue LLC held 6 shares of Gilead Sciences worth $759 as of Q2 2026.
  • NorthAvenue LLC left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up ﹤0.01% of NorthAvenue LLC's portfolio in Q2 2026, its #241 holding.
  • NorthAvenue LLC first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • NorthAvenue LLC's Gilead Sciences position peaked at $837 in Q1 2026.
  • 508 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on NorthAvenue LLC's 13F filing for Q2 2026, filed 21 Jul 2026.